financetom
Business
financetom
/
Business
/
Talisker Reduces Debt by $5.1 Million After Debenture Conversion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Talisker Reduces Debt by $5.1 Million After Debenture Conversion
Oct 3, 2025 6:08 AM

08:47 AM EDT, 10/03/2025 (MT Newswires) -- Talisker Resources ( TSKFF ) said Friday that it exercised its right to convert all of the outstanding principal amounts of its convertible debentures into common shares, reducing its debt by $5.1 million.

Talisker said it issued a $4 million convertible debenture to Phoenix Gold Fund in October 2024 and a $1.1 million convertible debenture to Spartan MM Fund in November 2024.

The debentures provide Talisker with a conversion right if the closing price of its shares on the Toronto Stock Exchange is at least 130% of the applicable conversion price for each of the 20 trading days before a notice of conversion is delivered to the holder.

As a result of the closing price of the shares on the TSX exceeding these thresholds, Talisker said it elected to convert all the outstanding principal amount of the Phoenix debenture into 8 million shares and all the outstanding principal amount of the Spartan debenture into 1,964,285 shares.

Talisker is advancing its flagship Bralorne gold project in British Columbia.

The company's share price dropped 4.5% Thursday to $1.50 on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
Mar 8, 2024
Novo Nordisk A/S’s head of development, Martin Holst Lange, expressed strong confidence in the drugmaker’s ability to launch the pill version of its experimental weight loss drug, amycretin, within this decade.  The optimism follows the announcement of robust early trial data.  The company said early trial data for its experimental obesity drug amycretin showed a higher weight loss than its Wegovy (semaglutide) treatment. In...
Rivian gains as new launch R2 SUV attracts strong early orders
Rivian gains as new launch R2 SUV attracts strong early orders
Mar 8, 2024
(Reuters) -Rivian shares rose about 4% on Friday as its cheaper R2 SUV racked up tens of thousands of reservations within hours of its launch, fueling optimism that the electric vehicle maker could expand in the mass-market segment. Unveiled on Thursday, the smaller R2 SUV, which will start at $45,000, has attracted more than 68,000 reservations, CEO RJ Scaringe said...
Algonquin Powers Up In Q4 But Skips Guidance On Uncertainty Over Renewables Sale
Algonquin Powers Up In Q4 But Skips Guidance On Uncertainty Over Renewables Sale
Mar 8, 2024
Algonquin Power & Utilities Corp. ( AQNB ) shares are trading higher after the company reported fourth-quarter FY23 results. Revenue declined 11% Y/Y to $666.9 million, beating the consensus of $653.0 million. The Regulated Services Group recorded a revenue decline of 11% Y/Y to $564.9 million, with Divisional Operating Profit growth of 11% led by the implementation of new rates and recovery...
SpaceX asks full 5th Circuit to review transfer of challenge to NLRB's structure
SpaceX asks full 5th Circuit to review transfer of challenge to NLRB's structure
Mar 8, 2024
* Texas judge said 'substantial' ties to California warranted transfer * Appeals panel declined to block transfer * SpaceX seeking review from full appeals court By Daniel Wiessner March 8 (Reuters) - Rocket maker SpaceX has asked a full U.S. appeals court to review a ruling rejecting the company's bid to keep its lawsuit challenging the structure of the National...
Copyright 2023-2026 - www.financetom.com All Rights Reserved